Medroxyprogesterone Acetate Dosing to Induce Menstruation
For inducing menstruation in secondary amenorrhea, give medroxyprogesterone acetate (Provera) 5-10 mg daily for 5-10 days, with 10 mg daily for 10 days being the optimal dose for adequate endometrial transformation. 1
Standard Dosing Protocol
The FDA-approved regimen for inducing withdrawal bleeding in women with secondary amenorrhea is straightforward:
- Dose range: 5-10 mg daily 1
- Duration: 5-10 days 1
- Optimal regimen: 10 mg daily for 10 days provides superior secretory transformation of the endometrium 1
- Timing: Therapy may be started at any time in cases of secondary amenorrhea 1
- Expected response: Progestin withdrawal bleeding typically occurs within 3-7 days after discontinuing therapy 1
Key Clinical Considerations
Prerequisite for Success
The endometrium must be adequately primed with estrogen (either endogenous or exogenous) for medroxyprogesterone to induce withdrawal bleeding effectively 1. If no bleeding occurs after completing the course, this suggests inadequate estrogen priming or other pathology requiring further evaluation 1.
When to Use Alternative Dosing
For abnormal uterine bleeding (not amenorrhea), the same 5-10 mg daily for 5-10 days regimen applies, but timing differs:
- Begin on calculated day 16 or 21 of the menstrual cycle 1
- 10 mg daily for 10 days starting on day 16 is suggested for optimal secretory transformation 1
For acute heavy bleeding requiring urgent control, research supports higher loading doses:
- 20 mg three times daily initially, then taper to 20 mg daily for 3 weeks 2
- High-dose protocols (60-120 mg on day 1, then 20 mg daily for 10 days) have shown effectiveness in adolescents with severe dysfunctional bleeding, though this exceeds FDA-approved dosing 3
Important Pitfalls to Avoid
Do not use medroxyprogesterone as a pregnancy test 1. Always confirm pregnancy status before initiating therapy, as there may be increased risk of minor birth defects if taken during the first 4 months of pregnancy 1.
Do not prescribe without considering contraindications:
- Active or history of breast cancer or other hormone-sensitive malignancies 1
- Undiagnosed abnormal vaginal bleeding (must rule out malignancy first) 1
- Active thromboembolic disease or history of blood clots 1
- Liver dysfunction 1
Follow-Up and Monitoring
- If withdrawal bleeding does not occur within 3-7 days after completing the 10-day course, investigate for inadequate estrogen levels or anatomic abnormalities 1
- For recurrent amenorrhea, planned menstrual cycling with medroxyprogesterone may be beneficial 1
- Re-evaluate patients every 3-6 months to determine if continued treatment is necessary 1
- No routine laboratory monitoring is required for short-term cyclic use to induce menstruation 4